A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs (HCV PMS)
Post-marketing Surveillance Study of Viekira/ Exviera Tablets for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs
Sponsor: AbbVie
A observational or N/A phase clinical study on Hepatitis C Virus (HCV), this trial is completed. The trial is conducted by AbbVie and has accumulated 19 data snapshots since 2017. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
19 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
▶ Show 14 earlier versions
-
Jan 2020 — Nov 2020 [monthly]
Completed
-
Aug 2019 — Jan 2020 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
May 2019 — Aug 2019 [monthly]
Active Not Recruiting
-
Mar 2019 — May 2019 [monthly]
Active Not Recruiting
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Recruiting
-
Sep 2018 — Jan 2019 [monthly]
Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Recruiting NA
-
Dec 2017 — Mar 2018 [monthly]
Recruiting NA
-
Oct 2017 — Dec 2017 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Aug 2017 — Oct 2017 [monthly]
Not Yet Recruiting NA
-
Jul 2017 — Aug 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .